Amplification of 3q26.2, 5q14.3, 8q24.3, 8q22.3, and 14q32.33 are possible common genetic alterations in oral cancer patients

dc.contributor.authorAmbele, M.A.
dc.contributor.authorvan Zyl, A.
dc.contributor.authorPepper, M.S.
dc.contributor.authorvan Heerden, M.B.
dc.contributor.authorvan Heerden, W.F.P
dc.contributor.departmentMichael S. Pepper: SAMRC Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, Institute for Cellular and Molecular Medicine, University of Pretoria, Pretoria, South Africaen_US
dc.date.accessioned2024-03-17T12:44:11Z
dc.date.available2024-03-17T12:44:11Z
dc.date.epub2020-04-30
dc.date.issued2020
dc.description.abstractThe lack of clinical biomarkers for head and neck cancer subtypes limits early diagnosis and monitoring of disease progression. This study investigates genetic alterations in clinically identical tumor, tumor-adjacent dysplastic epithelium (TADE) and normal epithelium (NE) in five oral cancer patients to identify differences and commonalities between oral cancer, TADE and NE. A VELscope®Vx device was used to identify TADE and NE surrounding a clinical tumor for analysis of genetic alterations using the OncoScan® assay. One of the tumor samples examined was an "M" class tumor with a high confidence BRAF:p.G469A:c.1406G>C somatic mutation, which is the first to be reported in oral cancer. Another tumor showed mosaicism in genetic alterations, indicating the presence of multiple clones. Overall, each patient's tumor, TADE and NE showed a distinct genetic profile which indicates intertumoral clonal/genetic diversity. Interestingly, four tumors showed gain of 3q26.2, 5q14.3, 8q24.3, 8q22.3, 14q32.33 and loss/LOH in 9p21.3 while all TADE had LOH on 22q11.23. In addition, some genetic alterations progressed from NE through TADE into tumor in individual patients. Furthermore, no molecular event was identified that is common to all NE and/or TADE that progressed into tumor. This pilot study demonstrates the presence of genetic heterogeneity in oral tumorigenesis, and suggests that there might exist some common genetic alterations between tumors and TADE. However, this observation would need to be further investigated and validated in a larger cohort of oral cancer patients for its potential role in oral tumorigenesis.en_US
dc.description.sponsorshipThis work was funded by the Cancer Association of South Africa (WFPvH) and the South African Medical Research Council (MSP—Flagship and Extramural Stem Cell Unit).en_US
dc.identifier.citationAmbele MA, van Zyl A, Pepper MS, van Heerden MB, van Heerden WFP. Amplification of 3q26.2, 5q14.3, 8q24.3, 8q22.3, and 14q32.33 are possible common genetic alterations in oral cancer patients. Front Oncol. 2020 Apr 30;10:683. doi:10.3389/fonc.2020.00683.en_US
dc.identifier.doi10.3389/fonc.2020.00683
dc.identifier.journalFrontiers in Oncologyen_US
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203479/
dc.identifier.urihttps://hdl.handle.net/11288/595527
dc.language.isoenen_US
dc.publisherGenetic Alterations in Oral Canceren_US
dc.research.unitStem Cell Research and Therapyen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectOncoScan® FFPE assayen_US
dc.subjectVELscope®Vx deviceen_US
dc.subjectOral squamous cell carcinomasen_US
dc.subjectHead and neck canceren_US
dc.subjectGenomic heterogeneityen_US
dc.subjectIntratumor clonal heterogeneityen_US
dc.titleAmplification of 3q26.2, 5q14.3, 8q24.3, 8q22.3, and 14q32.33 are possible common genetic alterations in oral cancer patientsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ambele MA_2020_Amplification of.pdf
Size:
565.56 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: